Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis.

Silvain J, Beygui F, Barthélémy O, Pollack C Jr, Cohen M, Zeymer U, Huber K, Goldstein P, Cayla G, Collet JP, Vicaut E, Montalescot G.

BMJ. 2012 Feb 3;344:e553. doi: 10.1136/bmj.e553. Review.

2.
3.

Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.

Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.

Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.

4.

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.

White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, Cohen M, Harrington RA, Chew DP, Petersen JL, Berdan LG, Aylward PE, Nessel CC, Ferguson JJ 3rd, Califf RM.

Am Heart J. 2006 Dec;152(6):1042-50. Erratum in: Am Heart J. 2007 Feb;153(2):327.

PMID:
17161049
5.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, Kereiakes DJ, Langer A, Mahaffey KW, Nessel CC, Armstrong PW, Avezum A, Aylward P, Becker RC, Biasucci L, Borzak S, Col J, Frey MJ, Fry E, Gulba DC, Guneri S, Gurfinkel E, Harrington R, Hochman JS, Kleiman NS, Leon MB, Lopez-Sendon JL, Pepine CJ, Ruzyllo W, Steinhubl SR, Teirstein PS, Toro-Figueroa L, White H; SYNERGY Trial Investigators.

JAMA. 2004 Jul 7;292(1):45-54.

PMID:
15238590
6.

Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.

Montalescot G, Zeymer U, Silvain J, Boulanger B, Cohen M, Goldstein P, Ecollan P, Combes X, Huber K, Pollack C Jr, Bénezet JF, Stibbe O, Filippi E, Teiger E, Cayla G, Elhadad S, Adnet F, Chouihed T, Gallula S, Greffet A, Aout M, Collet JP, Vicaut E; ATOLL Investigators.

Lancet. 2011 Aug 20;378(9792):693-703. doi: 10.1016/S0140-6736(11)60876-3.

PMID:
21856483
7.

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.

Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E; ExTRACT-TIMI 25 Investigators.

N Engl J Med. 2006 Apr 6;354(14):1477-88. Epub 2006 Mar 14.

8.

Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.

Brieger D, Collet JP, Silvain J, Landivier A, Barthélémy O, Beygui F, Bellemain-Appaix A, Mercadier A, Choussat R, Vignolles N, Costagliola D, Montalescot G.

Catheter Cardiovasc Interv. 2011 Feb 1;77(2):182-90. doi: 10.1002/ccd.22674.

PMID:
20578166
9.

Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.

Zeymer U, Gitt A, Jünger C, Bauer T, Heer T, Koeth O, Wienbergen H, Zahn R, Senges J.

Thromb Haemost. 2008 Jan;99(1):150-4. doi: 10.1160/TH07-07-0449.

PMID:
18217147
10.

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.

Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators.

Circulation. 2008 Nov 11;118(20):2038-46. doi: 10.1161/CIRCULATIONAHA.108.789479. Epub 2008 Oct 27. Erratum in: Circulation. 2008 Dec 16;118(25):e842.

11.

Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.

Li YJ, Rha SW, Chen KY, Jin Z, Wang L, Ramasamy S, Poddar KL, Minami Y, Park JY, Choi CU, Oh DJ, Jeong MH; Korea Acute Myocardial Infarction Registry Investigators.

J Cardiol. 2012 Jan;59(1):22-9. doi: 10.1016/j.jjcc.2011.09.005. Epub 2011 Nov 12.

12.

Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.

Lavi S, Cantor WJ, Casanova A, Tan MK, Yan AT, Džavík V, Fitchett D, Cohen EA, Borgundvaag B, Heffernan M, Ducas J, Goodman SG.

Am Heart J. 2012 Feb;163(2):176-81.e2. doi: 10.1016/j.ahj.2011.10.015.

PMID:
22305834
13.

Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?

Silvain J, Montalescot G.

Arch Cardiovasc Dis. 2012 May;105(5):259-61. doi: 10.1016/j.acvd.2012.03.002. Epub 2012 May 22. No abstract available.

14.

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM.

JAMA. 2004 Jul 7;292(1):89-96. Review.

PMID:
15238596
16.

Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).

Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW.

Am J Cardiol. 2009 May 1;103(9):1196-203. doi: 10.1016/j.amjcard.2009.01.030.

PMID:
19406258
17.

Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.

Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, Corrigan VE, Ryan TJ Jr, Breall JA, Moses JW, Eaton GM, Sklar MA, Lincoff AM; Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.

J Am Coll Cardiol. 2003 Jan 1;41(1):20-5.

18.

Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention.

James S.

BMJ. 2012 Feb 3;344:e712. doi: 10.1136/bmj.e712. No abstract available.

PMID:
22306481
19.

Can enoxaparin safely replace unfractionated heparin during coronary intervention in acute coronary syndromes?

Wolak A, Ayzenberg Y, Cafri C, Gilutz H, Ilia R, Zahger D.

Int J Cardiol. 2004 Aug;96(2):151-5.

PMID:
15262028
20.

Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D, Schömig A, Berger PB, Mehilli J; ISAR-REACT 4 Trial Investigators.

N Engl J Med. 2011 Nov 24;365(21):1980-9. doi: 10.1056/NEJMoa1109596. Epub 2011 Nov 13.

Items per page

Supplemental Content

Write to the Help Desk